Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

Rhea-AI Summary

Moderna (NASDAQ:MRNA) has announced its participation in the ESCMID Global Congress in Vienna from April 11-15, 2025, where it will present extensive infectious disease research through twelve scientific presentations.

The presentations include research across multiple disease areas: COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox. The format includes three oral presentations, one e-poster presentation, and eight poster presentations.

Key highlights include presentations on: JN.1 and KP.2-encoding mRNA COVID-19 vaccines, six-month immunogenicity of mRNA-1345 RSV vaccine in adults aged ≥60 years, safety studies of mpox vaccine candidate mRNA-1769, and long-term safety data for cytomegalovirus mRNA-1647 vaccine.

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025.

Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases.

COVID-19

• Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants - Oral Presentation
  Presenter: Frances Priddy
  Session: Advances in vaccine effectiveness for viral respiratory infections
  Date: April 12 | Time & Location: 11:00 (Hall 9)

• Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses - Oral Presentation
  Presenter: Spyros Chalkias
  Session: Vaccines and prophylaxis against respiratory viral infections
  Date: April 13 | Time & Location: 11:00 (Hall 9)

• Clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine - Poster Presentation
  Presenter: Spyros Chalkias
  Session: COVID-19
  Date: April 12 | Time & Location: 12:00 (Poster Hall)

• Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged ≥12 years - Poster Presentation
  Presenter: Christina Grassi
  Session: COVID-19
  Date: April 12 | Time & Location: 12:00 (Poster Hall)

RSV

• Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years - E-Poster Presentation
  Presenter: Mihir Desai
  Session: On the frontiers of vaccine-driven prevention
  Date: April 12 | Time & Location: 08:30 (Arena 1)

• Safety and immunogenicity of mRNA-1345 revaccination at 24 months in adults ≥60 years - Poster Presentation
  Presenter: Mihir Desai
  Session: Clinical Trials
  Date: April 15 | Time & Location: 12:00 (Poster Hall)

• Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States - Poster Presentation
  Presenter: Clarisse Demont
  Session: Influenza and respiratory viruses
  Date: April 12 | Time & Location: 12:00 (Poster Hall)

• Association of virology swab positivity in adults aged ≥40 years with Computerized Medical Record Reported Acute Respiratory Infection (ARI) Subgroups: Observational Study of ARI (ObservatARI) - Poster Presentation
  Presenter: Simon De Lusignan
  Session: Influenza and respiratory viruses
  Date: April 12 | Time & Location: 12:00 (Poster Hall)

Mpox

• Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial - Oral Presentation
  Presenter: Hiwot Hiruy
  Session: Novel vaccines in clinical development
  Date: April 14 | Time & Location: 17:30 (Hall 3)

Cytomegalovirus

• Long-term safety and immunogenicity of cytomegalovirus mRNA-1647 vaccine in healthy adults: 36-month results from a phase 2 extension trial - Poster Presentation
  Presenter: Ben Lorenz
  Session: Clinical Trials
  Date: April 15 | Time & Location: 12:00 (Poster Hall)

Influenza

• Six-month persistence and safety of mRNA-based influenza or multicomponent influenza/COVID-19 vaccines versus licensed comparators in adults aged ≥18 years - Poster Presentation
  Presenter: Mieke Soens
  Session: Influenza and respiratory viruses
  Date: April 12 | Time & Location: 12:00 (Poster Hall)

Norovirus

• Incidence and severity of sporadic, medically attended norovirus infection in the United States, 2023-2024 - Poster Presentation
  Presenter: Mark A. Schmidt
  Session: Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology
  Date: April 12 | Time & Location: 12:00 (Poster Hall)

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for Moderna's vaccine candidates to alleviate disease outcomes. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.Mirceawillats@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna Inc.

View the original press release on ACCESS Newswire

FAQ

What research will Moderna present at ESCMID 2025?

Moderna will present 12 scientific presentations covering COVID-19, influenza, RSV, CMV, norovirus, and mpox research at ESCMID 2025 in Vienna from April 11-15.

What are the key COVID-19 vaccine studies MRNA will present?

MRNA will present studies on JN.1 and KP.2-encoding vaccines, including immunogenicity data and relative vaccine efficacy of SARS-CoV-2 spike receptor-binding and N-terminal domain vaccines.

What RSV vaccine data will MRNA showcase at ESCMID 2025?

MRNA will present six-month immunogenicity data for mRNA-1345 RSV vaccine in adults ≥60 years and 24-month revaccination safety data.

What are the latest developments in MRNA's mpox vaccine research?

MRNA will present interim analysis results from a Phase 1/2 trial on the safety and immunogenicity of their mpox vaccine candidate mRNA-1769.